SEC Comment Letter for GALECTIN THERAPEUTICS INC (GALT) (CIK 0001133416) (GALT) — Dec 20, 2011
GALECTIN THERAPEUTICS INC (GALT) (CIK 0001133416)
Date: Dec. 20, 2011 · CIK: 0001133416 · Accession: 0000000000-11-072721
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-31791
Letter
December 20, 2011 Via E-mail Peter G. Traber, M.D. Chief Executive Officer and President Galectin Therapeutics Inc. 7 Wells Avenue Newton, MA 02459 Re: Pro-Pharmaceuticals, Inc., now kn own as Galectin Therapeutics Inc. Form 10-K for the Fiscal Year Ended December 31, 2010 Filed March 15, 2011 File No. 001-31791
Dear Dr. Traber: We have completed our review of your f iling. We remind you that our comments or changes to disclosure in res ponse to our comments do not for eclose the Commission from taking any action with respect to the company or th e filing and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the fi ling to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.
Sincerely,
/s/ Jennifer Riegel for
Show Raw Text
December 20, 2011 Via E-mail Peter G. Traber, M.D. Chief Executive Officer and President Galectin Therapeutics Inc. 7 Wells Avenue Newton, MA 02459 Re: Pro-Pharmaceuticals, Inc., now kn own as Galectin Therapeutics Inc. Form 10-K for the Fiscal Year Ended December 31, 2010 Filed March 15, 2011 File No. 001-31791 Dear Dr. Traber: We have completed our review of your f iling. We remind you that our comments or changes to disclosure in res ponse to our comments do not for eclose the Commission from taking any action with respect to the company or th e filing and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the fi ling to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Jennifer Riegel for Jeffrey Riedler Assistant Director